Millions of babies and children undergo anaesthesia every year. Preclinical evidence shows that all common anaesthetic drugs are associated with neuro-apoptosis and neurodevelopmental deficits in immature rodent models. Xenon, a low-potency anaesthetic gas, renowned for producing cardiostable anaesthesia and with neuroprotective properties in multiple pathologies, was recently used to reduce sevoflurane requirements of babies and young children undergoing cardiac catheterisation. Preclinical studies have shown the addition of xenon reduced neuroapoptosis induced by 0.7% isoflurane in vivo and in vitro.
- Standards for Preclinical Research and Publications in Developmental Anaesthetic Neurotoxicity: Expert Opinion Statement From the SmartTots Preclinical Working Group
- Search Announcement: Medical Officer
- Anesthesia for Major Surgery in the Neonate
- Best Pharmaceuticals for Children Act (BPCA) Priority Releases 2020-2021 List of Needs in Pediatric Therapeutics
- HSP90 inhibitor 17AAG attenuates sevoflurane-induced neurotoxicity in rats and human neuroglioma cells via induction of HSP70